Stoke Therapeutics filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing RNA medicines, including zorevunersen for Dravet syndrome. Recent 8-K reports cover quarterly financial results, clinical-program updates, capital resources, material agreements, lease obligations, board appointments, executive compensation, auditor changes, and Regulation FD disclosures.
The company’s definitive proxy materials describe annual meeting voting matters, director elections, board committee structure, governance practices, equity compensation, and related stockholder information. Filings also identify its common stock registered on the Nasdaq Global Select Market under STOK.
Amendment No. 5 to Schedule 13D updates the ownership position of the reporting group — Skorpios Trust, Montrago Trustees Ltd., Blue Horizon Enterprise Ltd. and Ezbon International Ltd. — in Stoke Therapeutics (STOK).
The group now reports beneficial ownership of roughly 6.23 million shares, or 11.4 % of the 54.6 million shares outstanding as disclosed in STOK’s 30 April 2025 10-Q. Current individual blocks are:
- Blue Horizon: 2,967,621 shares (5.4 %) with shared voting/dispositive power
- Montrago Trustees & Skorpios Trust: 3,256,181 shares each, reflecting the same 6 % stake held jointly
- Ezbon International: 288,560 shares (0.5 %)
Key event: On 18 June 2025 Ezbon sold 650,000 shares at $11.00 in an open-market trade, cutting its holdings by ~69 % and raising about $7.2 million. No other trades were reported within the past 60 days.
A new Joint Filing Agreement dated 23 June 2025 is filed as Exhibit 1. Aside from Ezbon’s sale, prior disclosures remain unchanged.
While the group continues to exceed the 10 % threshold, Ezbon’s sizable disposal may signal reduced conviction or liquidity needs, and could introduce incremental supply pressure if additional sales follow. Investors should monitor forthcoming filings for further changes to this concentrated insider position.
Stoke Therapeutics (STOK) – Form 3 initial beneficial ownership disclosure
Chief Patient Officer Jason Hoitt has filed his first Section 16 statement. He directly owns 1,802 common shares of Stoke Therapeutics. In addition, he holds 480,000 employee stock options across four grants: 265,000 options at $12.21 expiring 04/14/2034; 65,000 at $14.25 expiring 08/14/2034; 60,000 at $8.33 expiring 03/19/2035; and 90,000 at $11.70 expiring 06/15/2035. Vesting schedules follow the standard 25% cliff after one year, with the remainder vesting monthly, subject to continued employment. Hoitt was also granted 40,000 restricted stock units (RSUs) that vest 25% annually starting 03/15/2026.
The filing is informational only—no shares were bought or sold. While the equity package is meaningful for the executive, it represents a small fraction of the company’s total shares outstanding and is unlikely to move the market. Nonetheless, the disclosure demonstrates alignment of management incentives with shareholder interests.